Arcturus Therapeutics

Arcturus Therapeutics News & Events

Arcturus Therapeutics To Present At 2016 BIO International Convention in San Francisco

June 1, 2016

San Diego, Calif., June 1, 2016 – Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, announced today that its President & CEO, Joseph E. Payne, has been invited to present during the “Delivery: The Next Frontier of Biotherapeutics” session at the 2016 BIO International Convention in San Francisco on Tuesday, June […]

Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology

March 16, 2016

San Diego, Calif., March 16th, 2016 – Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, announced today that the European Patent Office (EPO) has issued a notice of its intent to grant the Company’s fundamental UNA Oligomer™ technology (EP Application No. 08780679.0), titled “Oligomers for Therapeutics.” “We are delighted with the […]

Arcturus Therapeutics Selected to Present at Biotech Showcase™ 2016

January 6, 2016

San Diego, Calif., January 6th, 2016 – Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, is pleased to announce that the Company has been selected to deliver a corporate presentation at the 8th annual Biotech Showcase™ conference being held January 11-13, 2016 during the JP Morgan Healthcare Conference in San Francisco, […]

Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research Collaboration and License Agreement to Develop RNA Therapeutics for Rare Diseases

October 29, 2015

NOVATO, CA – October 29, 2015 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Arcturus Therapeutics, Inc., a leading RNA medicines company, today announced that they have entered into a research collaboration and license agreement to discover and develop messenger RNA […]

Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications

June 11, 2015

San Diego, Calif., June 11, 2015 – Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen). Under the agreement, facilitated by J&J Innovation, the parties will work together to develop and commercialize RNA-based drug products for the […]

Precision NanoSystems and Arcturus Therapeutics Announce a Partnership for the Manufacture of RNA Medicines

January 9, 2015

Vancouver, Canada, Jan 9, 2015 – Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, today announced a partnership for the manufacture of RNA medicines. Under the terms of the […]